{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06136585",
            "orgStudyIdInfo": {
                "id": "23-378"
            },
            "organization": {
                "fullName": "The Cleveland Clinic",
                "class": "OTHER"
            },
            "briefTitle": "Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial",
            "officialTitle": "Comparison of Efficacy of Sugammadex Versus Neostigmine in Reversing Neuromuscular Blocks in Patients Having Outpatient Endoscopic Retrograde Cholangiopancreatography (ERCP). A Randomized, Double-Blinded Trial",
            "therapeuticArea": [
                "Other"
            ],
            "study": "sugammadex-vs-neostigmine-in-reversing-neuromuscular-blocks-in-outpatient-ercp-a-randomized-double-blinded-trial"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-10-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-13",
            "studyFirstSubmitQcDate": "2023-11-13",
            "studyFirstPostDateStruct": {
                "date": "2023-11-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-28",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Ryu Komatsu",
                "investigatorTitle": "MD",
                "investigatorAffiliation": "The Cleveland Clinic"
            },
            "leadSponsor": {
                "name": "The Cleveland Clinic",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Merck Sharp & Dohme LLC",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The investigators propose a single-center,assessor-Blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neostigmine in patients undergoing Endoscopic retrograde cholangiopancreatography at Cleveland Clinic Main Campus.",
            "detailedDescription": "The investigators propose a single-center, assessor-blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neostigmine. Participating patients and outcome assessors will be blinded to group assignment. The anesthesiologists who assume anesthesia care will not be blinded to group assignment.\n\nAmerican Society of Anesthesiologists (ASA) physical status 3 and 4 adults scheduled for elective outpatient ERCP procedure with general anesthesia at Cleveland Clinic Main Campus will be included in the study. Patients will be excluded if they have suspected difficult airway, neuromuscular disorders, end-stage renal disease requiring hemodialysis, are allergic to fentanyl, neuromuscular blocking drugs or neuromuscular reversal drugs, or are pregnant or breastfeeding.\n\nEighty patients scheduled for outpatient ERCP with general anesthesia and rocuronium-induced muscle relaxation will be randomized 1:1 to: 1) reversal by sugammadex; or 2) reversal by neostigmine. Randomization will be stratified by 2 factors: (1) patient's age (older than 60 versus younger than 60) and (2) diagnostic vs. interventional procedures. Randomization will be based on computer generated codes that will be maintained in web-based system until shortly before induction of anesthesia, thus concealing allocation so long as practical."
        },
        "conditionsModule": {
            "conditions": [
                "Neuromuscular Blocks"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "maskingDescription": "A single-center, Assessor-Blinded, parallel group randomized trial",
                    "whoMasked": [
                        "PARTICIPANT",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "2 mg/kg sugammadex",
                    "type": "EXPERIMENTAL",
                    "description": "All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 2 mg/kg sugammadex.",
                    "interventionNames": [
                        "Drug: 2 mg/kg sugammadex"
                    ]
                },
                {
                    "label": "0.07 mg/kg neostigmine",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 0.07 mg/kg neostigmine (to a maximum of 5 mg).",
                    "interventionNames": [
                        "Drug: 0.07 mg/kg neostigmine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "2 mg/kg sugammadex",
                    "description": "All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 2 mg/kg sugammadex.",
                    "armGroupLabels": [
                        "2 mg/kg sugammadex"
                    ],
                    "otherNames": [
                        "All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 2 mg/kg sugammadex."
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "0.07 mg/kg neostigmine",
                    "description": "All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 0.07 mg/kg neostigmine (to a maximum of 5 mg).",
                    "armGroupLabels": [
                        "0.07 mg/kg neostigmine"
                    ],
                    "otherNames": [
                        "All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 0.07 mg/kg neostigmine (to a maximum of 5 mg)."
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Time required from reversal of neuromuscular block to discharge readiness",
                    "description": "To assess the time required from reversal of neuromuscular block to discharge readiness in patients randomized to sugammadex or neostigmine.",
                    "timeFrame": "First 24 hours after reversal of neuromuscular block"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Incidence of postoperative nausea and vomiting (PONV) in patients randomized to sugammadex or neostigmine.",
                    "description": "Incidence of postoperative nausea and vomiting (PONV) in patients randomized to sugammadex or neostigmine.",
                    "timeFrame": "2 hours of post anesthetic recovery"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* \u226518 years old\n* American Society of Anesthesiologist physical status 3-4\n* Scheduled for outpatient endoscopic retrograde cholangiopancreatography\n\nExclusion Criteria:\n\n* Difficult Airway\n* Neuromuscular Disorders (eg: ALS, Botulism, Myasthenia Gravis, Lambert-eaton syndrome)\n* End stage renal disease requiring dialysis\n* Pregnancy or breast-feeding\n* Allergy to Fentanyl\n* Allergy to Neuromuscular blocking drugs (eg: rocuronium)\n* Allergy to Neuromuscular reversal drugs (eg: sugammadex or neostigmine)\n* Allergy to glycopyrrolate",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Aline Reuter Pimenta",
                    "role": "CONTACT",
                    "phone": "216-445-7530",
                    "email": "REUTERA2@ccf.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Ryu Komatsu, MD",
                    "affiliation": "The Cleveland Clinic",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Cleveland Clinic Foundation",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Aline Reuter Pimenta",
                            "role": "CONTACT",
                            "phone": "216-445-7530",
                            "email": "REUTERA2@ccf.org"
                        },
                        {
                            "name": "Ryu Komatsu, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "21704815",
                    "type": "BACKGROUND",
                    "citation": "Cotton PB. Are low-volume ERCPists a problem in the United States? A plea to examine and improve ERCP practice-NOW. Gastrointest Endosc. 2011 Jul;74(1):161-6. doi: 10.1016/j.gie.2011.03.1233. No abstract available."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009388",
                    "term": "Neostigmine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002800",
                    "term": "Cholinesterase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018678",
                    "term": "Cholinergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000010277",
                    "term": "Parasympathomimetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12333",
                    "name": "Neostigmine",
                    "asFound": "Chronic Lymphocytic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6040",
                    "name": "Cholinesterase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20758",
                    "name": "Cholinergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}